Finance & markets · 18/11/20261 min read
Biocon's Pertuzumab Receives Marketing Authorization in EU, First Biosimilar Authorized Under EMA's New Tailored Clinical Approach
Summary
EC approval follows recent U.S. FDA approval of Biocon's pertuzumab biosimilar Provides an additional treatment option for patients with HER2-positive breast cancer and may support more sustainable healthcare systems in Europe The milestone further strengthens Biocon's growing oncology...